The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

• Published in: Alzheimer's & dementia Vol. 13; no. 5; pp. 561 - 571
• Main Authors: Weiner, Michael W, Veitch, Dallas P, Aisen, Paul S, Beckett, Laurel A, Cairns, Nigel J, Green, Robert C, Harvey, Danielle, Jack, Clifford R, Jagust, William, Morris, John C, Petersen, Ronald C, Salazar, Jennifer, Saykin, Andrew J, Shaw, Leslie M, Toga, Arthur W, Trojanowski, John Q
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2017; Elsevier
• Subjects: 60 APPLIED LIFE SCIENCES; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - physiopathology; Alzheimer's disease; Amyloid phenotyping; Biomarkers - cerebrospinal fluid; Brain - diagnostic imaging; Brain Health Registry; Centiloid method; Clinical trial biomarkers; Clinical Trials as Topic; Disease Progression; Functional connectivity; Humans; Magnetic Resonance Imaging; Neuroimaging; Neurology; Positron-Emission Tomography; Radionuclide Imaging; Tau imaging; Tau imaging; Brain Health Registry; Functional connectivity; Clinical trial biomarkers; Amyloid phenotyping; Centiloid method; Alzheimer's disease

Abstract Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods ADNI-3 will follow curren...